Skip to main content

Table 1 Characteristics of study subjects and healthy volunteers.

From: Eotaxin-1 in exhaled breath condensate of stable and unstable asthma patients.

Characteristics

Dimension

Healthy volunteers

Steroid naïve asthma

Stable ICS-treated asthma

Unstable ICS- treated asthma

Number of patients

 

12

14

16

16

Sex

F/M

6/6

8/6

9/7

10/6

Age

Years

25.40 ± 5.20

25.00 ± 6.30

39.50 ± 10.70

45.80 ± 7.30

Duration of symptoms

Years

 

2.71 ± 1.08

10.80 ± 6.20*Δ

17.06 ± 6.50*+

Baseline FEV1

% pred

102.50 ± 9.1

89.20 ± 12.00 Δ

80.80 ± 7.10 Δ

51.50 ± 11.70*+

FEV1/FVC ratio

%

86 ± 7

73 ± 8

64 ± 10

56 ± 12

Serum total IgE concentration

kU/L

61.08 ± 25.50*

248.4 ± 202.3

232.5 ± 79.0

318.0 ± 98.0

Blood eosinophil count

cells/mm3

56 ± 22*

212 ± 88

281 ± 73

302 ± 95

FENO

ppB

15.80 ± 5.06*

75.21 ± 37.13+

39.40 ± 12.50*Δ

64.70 ± 25.04+

Eotaxin-1 (EBC)

pg/ml

6.24 ± 0.70*

9.70 ± 1.70Δ

10.45 ± 2.00Δ

17.97 ± 3.60*+

ECP (serum)

μg/l

3.87 ± 0.81*

13.21 ± 4.56

12.80 ± 3.50 Δ

21.90 ± 8.40*+

ICS

μg/day

  

359 ± 128

1078 ± 269

Positive SPT

     

mite/cat/moulds

  

14/2/3

14/4/4

15/4/6

  1. Data are presented as medians (ranges)
  2. FEV1- forced expiratory volume in one second
  3. * Values significantly different from patients with steroid-naïve asthma, p < 0.05
  4. + Values significantly different from patients with stable, ICS-treated asthma, p < 0.05
  5. Δ Values significantly different from patients with unstable, ICS-treated asthma, p < 0.05
  6. ICS - inhaled corticosteroids (Fluticasone propionate equivalent)
  7. SPT - skin prick tests (number of patients)